Historical Stock Chart
5 Years : From Jan 2012 to Jan 2017
RNS Number : 4391A
02 April 2012
For immediate release 2 April 2012
("Abcam" or "the Company")
Total Voting Rights - Voting Rights and Capital
In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: The Company's issued share capital consists of 183,620,579 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury. The above figure of 183,620,579 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
Date of Notification: 2 April 2012
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Numis Securities - Nominated Advisor
and Joint Broker + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated
James Black - Corporate Broking
Peel Hunt LLP - Joint Broker
Andy Crossley - Corporate Broking + 44 (0) 20 7418 8900
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.
Abcam now has an online catalogue of over 89,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.
This information is provided by RNS
The company news service from the London Stock Exchange